FY26 Results: Swings to Net Loss on Impairment Charge, Acquires Kenalog® Brand
Piramal Pharma Limited · PPLPHARMA · NSE ·
Reported a net loss of ₹325.94 crore for FY26, a sharp decline from a net profit of ₹91.13 crore in the previous year. The loss was primarily driven by a significant one-time impairment charge of ₹175.82 crore on an intangible asset under development. Revenue from operations rema…